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FORMULASI DAN PENILAIAN SISTEM PENGHANTARAN DRUG 
AZITROMISIN PENGEMULSIAN-KENDIRI UNTUK MENINGKATKAN 
PENEMBUSANNYA MELALUI PERSIMPANGAN KETAT EPITELIUM  
 
ABSTRAK 
                   Azithromisin (AZM) adalah antibiotik makrolida yang digunakan untuk 
rawatan beberapa jangkitan bakteria. Ia diketahui mempunyai bioavailabiliti oral 
rendah (37%) disebabkan oleh berat molekulnya yang tinggi, kelarutan tidak lengkap 
dan /atau kebolehtelapan usus yang rendah, yang berpotensi menyekat penyerapan 
usus. Untuk mengatasi kekurangan ini, sistem penghantaran drug cecair 
pengemulsiaan-kendiri dan pepejal (L-SEDDs dan S-SEDDs) AZM telah disediakan 
dalam usaha untuk meningkatkan keterlarutan, dan mengubah penembusan selular 
yang mungkin meningkatkan bioavailabiliti oral. Lapan gambarajah pseudo-ternari 
yang berbeza dibina berdasarkan kelarutan AZM dan kajian emulsifikasi dalam 
pelbagai jenis SEDD eksipien pada nisbah surfaktandan ko-surfaktan (Smix) yang 
berbeza. Kriteria pemilihan ialah ukuran titisan (DS) <150 nm, polidispersiti (PdI) ≤ 
0.7, dan transmitan (T)% > 85 dalam tiga pencair, air suling (D.H2O), 0.1 mM HCl 
dan simulasi usus cecair (SIF), serta kandungan drug tertinggi. Formulasi akhir L-
SEDD (F1 (H)), yang terdiri daripada Capryol 90
®, Tween 20®, dan Transcutol HP® 
masing-masing sebanyak 22.22%, 51.85% dan 25.93% (v/v) boleh memenuhi cirri-
ciri pemilihan dan mempunyai DS 141.57 ± 1.1 nm, PdI 0.52 ± 0.004, T% 90.1 ± 0.1, 
dan kandungan drug 60.42 ± 0.4 mg/ml (p < 0.05). Oleh itu, ia telah dipilih untuk 
penukaran kepada S-SEDDs menggunakan agen pemejalan yang berlainan. Aerosil 
200® menghasilkan S-SEDD (FS-A200) dengan DS paling kecil 155.3 ± 1.91 nm, PdI 
0.62 ± 0.03, dan kandungan drug 38.79 ± 0.52 mg/g (p nilai-nilai < 0.05). Formula 
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blank F1(H) dan FS-A200 terbukti selamat pada kepekatan yang berbeza dalam ujian 
sitotoksisiti microtiter tetrazolium (MTT). Blank dan AZM yang digabungkan dalam 
formulasi F1(H) dan FS-A200 mampu memodulasi ekalapis sel Caco-2 dengan 
mengurangkan rintangan transepithelial berbanding AZM tulen. Tambahan pula, 
formulasi AZM-F1(H) dan AZM-FS-A200 telah meningkatkan pembebasan AZM dalam 
D.H2O, 0.1 mM HCl, dan SIF jika dibandingkan dengan AZM tulen dengan 
pelepasan> 90% dalam 5 minit dan 60 minit masing-masing oleh AZM-F1(H) dan 
AZM-FS-A200 (p < 0.05). Kajian kestabilan menunjukkan bahawa formulasi AZM-
F1(H) dan AZM-FS-A200 stabil dalam keadaan penyimpanan peti sejuk dengan jangka 
hayat anggaran masing-masing sebanyak 39.29 dan 40.29 bulan.  
Kesimpulannya, kedua pengemulsian-kendiri sistem penghantaran drug bermuatan 
azitromicin dalam bentuk cacair dan pepejal telah berjaya menigkatkan kelarutan dan 
kadar pelarutan apabila dibandinkan dengan drug bebas tanpa formulasi. Formulasi ini 
telah terbukti selamat dan berupaya membuka persimpangan ketat transepitelial yang 
akan meningkatkan pengankutan paraselular. 
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FORMULATION AND EVALUATION OF SELF-EMULSIFYING DRUG 
DELIVERY SYSTEM OF AZITHROMYCIN TO ENHANCE ITS 
PENETRATION THROUGH THE EPITHELIAL TIGHT JUNCTIONS 
 
ABSTRACT 
                   Azithromycin (AZM) is a macrolide antibiotic used for the treatment of a 
number of bacterial infections. It is known to have a low oral bioavailability (37 %) 
due to its relatively high molecular weight, incomplete solubility and/or poor intestinal 
permeability, which is potentially restricting its intestinal absorption. To overcome 
these drawbacks liquid and solid self-emulsifying drug delivery systems (L-SEDDs 
and S-SEDDs) of AZM were prepared in an attempt to enhance its solubility, and 
altering its cellular penetration, which might improve its oral bioavailability. Eight 
different pseudo-ternary diagrams were constructed based on AZM solubility and 
emulsification studies in different SEDDs excipients at different surfactant to co-
surfactant (Smix) ratios. The selection criteria was droplet size (DS) < 150 nm, 
polydispersity index (PdI) ≤ 0.7, and transmittance (T) % > 85 in three diluents of 
distilled water (D.H2O), 0.1 mM HCl, and simulated intestinal fluids (SIF) as well as 
highest drug content. A final L-SEDDs formulation (F1(H)), which is composed of 
Capryol 90®, Tween 20®, and Transcutol HP® at the concentrations of 22.22 %, 51.85 
%, and 25.93 % (v/v) respectively, was able to meet the selection criteria and had a 
DS of 141.57 ± 1.1 nm, PdI 0.52 ± 0.004, T% 90.1 ± 0.1, and drug content of 60.42 ± 
0.4 mg/ml (p < 0.05). Accordingly, it was selected for conversion to S-SEDDs using 
different solidifying agents. Aerosil 200® produced S-SEDDs (FS-A200) with the 
smallest DS of 155.3 ± 1.91 nm, PdI 0.62 ± 0.03, and drug content of 38.79 ± 0.52 
mg/g (p < 0.05). Blanks of F1(H) and FS-A200 formulations proved to be safe at different 
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concentrations upon evaluating them in the microtiter tetrazolium (MTT) cytotoxicity 
assay. Blank and AZM incorporated F1(H) and FS-A200 formulations were able to cross 
through the Caco-2 cell monolayer through reducing their transepithelial electrical 
resistance in comparison to the pure AZM. Furthermore, AZM-F1(H) and AZM-FS-
A200 formulations have increased the release of AZM in D.H2O, 0.1 mM HCl, and SIF 
when compared to the pure AZM with a fast release of > 90% in 5 min and 60 min by  
AZM-F1(H) and AZM-FS-A200 respectively (p values < 0.05). The stability study 
revealed that AZM-F1(H) and AZM-FS-A200 formulations are stable at refrigerator 
storage conditions with estimated shelf life of 39.29 and 40.29 months respectively.  
In conclusions, both azithromycin loaded liquid and solid self-emulsifying drug 
delivery systems have successfully enhanced azithromycin’s solubility, and 
dissolution rate in comparison to the free azithromycin. The formulations were proven 
safe and capable of opening the transepithelial tight junctions, which would enhance 
the drug paracellular transport. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Routes of drug administration: oral drug delivery 
A wide range of pharmaceutical and biotechnological products as well as natural 
compounds are delivered through various routes of administrations such as oral, 
parenteral (I.V., S.C. and I.M. injections) and topical. The parenteral route is mainly 
limited by the patient’s discomfort, sometimes being expensive, and complications due 
to un-sterile tools; which leads to infections at the side of administration (Jin et al., 
2015). On the other hand, oral route’s products represent two-third of the 
pharmaceutical dosage forms, as it is a more convenient and comfortable route of drug 
administration, economical and often safer, and requires no special training to take the 
medication (Al-Achi et al., 2013). 
In some cases, achieving therapeutic levels of drugs by oral route may represent  a 
complicated process, which includes overcoming some challenges like drug poor 
solubility, low bioavailability, instability in gastric acid medium, drug-food 
interaction, and poor absorption through the gastrointestinal tract (GIT) mucosal 
barrier (Ensign et al., 2012; Lambkin & Pinilla, 2002). The proper design of an oral 
dosage form can successfully overcome most if not all of that.  
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1.2 Biopharmaceutical classification system (BCS) 
The U.S. Food and Drug Administration (USFDA) classified oral drugs in bio-
pharmaceutical classification system (BCS) into four classes based on its aqueous 
solubility, and intestinal permeability (as shown in figure 1.1). Practically, a 
biopharmaceutical behaviour of a drug is determined by studying its aqueous solubility 
at different pH values ranging from 1 to 6.8. Its dissolution rate is identified by using 
one of the U.S. Pharmacopeia (USP) apparatus that are specifically selected along with 
certain dissolution conditions to suit the tested drug based on its USP dissolution 
profile. The intestinal permeability can be observed on different experimental levels 
either in vitro (human or animal tissue, as well as suitable epithelial cell monolayer 
cultures), in situ intestinal perfusions, or in vivo (humans or animal models) (USFDA, 
2015).   
 
 
Figure 1.1: The biopharmaceutical classification system of drugs (BCS) 
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According to the BCS classification, class I drug substances does not require 
bioavailability and bioequivalence studies due to their high dissolution rate and 
bioavailability. However, drug in class II and class III require bioavailability and 
bioequivalence studies. This is because the drugs under class II have a high 
permeability but low solubility, and low dissolution rate, which in turn lead to a poor 
oral bioavailability. While the drugs in class III, have low and variable bioavailability 
due to poor penetration in the intestinal membrane, although the dosage forms have 
good solubility and dissolution rate. Class IV is suggested to be not suitable for oral 
dosage form, due to its low solubility and permeability (Ku, 2008; Junghanns & 
Müller, 2008).  
 
1.3 Classification of the lipid based drug delivery systems  
Creativity in applying natural and synthetic oils, lipids and fatty acids to improve 
solubility of poorly soluble drug and bioavailability has generated remarkable 
experimental outcomes that lead to academic and commercial successes. One of the 
earliest definitions of lipid-based formulations is an oil/surfactant mixture (Pouton, 
1985). Various literatures were linking the beneficial impacts of fatty food or oils on 
drug substances bioavailability (Piscitelli et al., 2011; Sim et al., 2005; Humberstone 
& Charman, 1997; Gourlay et al., 1989). The first classification of this lipid based 
formulations was introduced in 2000 (Pouton, 2000), while in 2006 additional class 
was added (Pouton, 2006). 
 
1.3.1 Formulation of type I systems 
The drug substance in this formulation is dissolved in a vegetable oil or a medium 
chain triglyceride (MCT), diglycerides and/or mono-glycerides based on the drug 
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degree of hydrophobicity. Usually, type I materials is labelled as “generally regarded 
as safe” (GRAS). The triglyceride is rapidly digested by pancreatic enzyme forms a 
colloidal dispersion having a coarse particle size. This will enhance intestinal 
transcellular absorption, and hence drug’s bioavailability. For many years, oil-soluble 
vitamins (A and D) were administered through this system. However, this formulation 
is restricted for highly lipophilic drugs (Pouton, 2000; Pouton, 2006).  
 
1.3.2 Formulation of type II system 
This formulation involves type I constituents, in addition to a lipophilic surfactant with 
hydrophilic-lipophilic balance (HLB <12). Excipients with medium chain, mono, di 
and/or tri-glycerides, shows superior results in terms of stability if surfactant 
concentration is more than 25 %w/w in the formula. However, increasing the 
surfactant concentration to more than 65 %w/w turns the final formulation into a 
viscous liquid crystalline phase with slower emulsification time. Following the oral 
intake, the digestion of this type will form a turbid oil/water dispersion (o/w), with a 
particle size ranging from 0.25 to 2 µm (Pouton, 2006). Nevertheless, the type II 
system has not attracted much attention within the pharmaceutical industry. This might 
be due to the commonly used surfactants for type II formulation, which are not 
included in the USFDA list of inactive ingredients (Sarita et al., 2012). 
 
1.3.3 Formulation of type III systems 
In this formulation, both hydrophilic and hydrophobic components were used (Pouton 
& Porter, 2008). Usually, surfactants with HLB >12 are employed either surfactant 
with the primary type I lipid materials, or surfactant, co-solvents and the primary type 
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I lipid materials. Some literatures split type III into two sub-categories including type 
IIIA, which contains less water-soluble surfactants and/or co-solvents, and type IIIB, 
which contains a higher portion of water-soluble contents (Holban & Grumezescu, 
2016; Pouton, 2006). The particle size range of this type of formulations is 100 to 250 
nm, with clear or almost clear dispersion. However, if the surfactant content is 
increased ≥ 40 % (under gentile agitation conditions), fine dispersions of <100 nm 
might be produced (Constantinides, 1995). Drug substances with lipophilicity partition 
coefficient (log P) from 2 to 4 showed an increase in the formulation solvent capacity 
and optical clarity. Type III formulations were named as self-emulsifying drug 
delivery system (SEDDs). SEDDs have been used successfully to overcome the 
biopharmaceutical drawbacks of many drugs. Consequently, various drugs are 
available in the market in SEDDs form such as Sandimmune® and Neoral® 
(Cyclosporin A), Fortovase® (Saquinavir) and Norvir® (Ritonavir) (Robert, 2007).  
 
1.3.4 Formulation of type IV systems 
These formulations have totally excluded the presence of the oil phase, and entirely 
depend on the selection of a proper mixture between hydrophilic surfactants and co-
solvents producing formulations with a particle size range from 50 to 100 nm. Upon 
dilution, a micellar solution is formed instead of dispersion due to the dominated 
presence of surfactant, which can lead to solvent capacity loss (Holban & Grumezescu, 
2016; Pouton & Porter, 2008). The co-solvent role is to facilitate the surfactant’s 
dispersion and to reduce the irritancy that might be caused by the high surfactant 
concentrations in some formulations. These systems are compatible with few drugs, a 
commercial example of this type is the capsule of the HIV protease inhibitor 
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amprenavir (Agenerase®, GSK) (Strickley, 2004). The typical composition of various 
types of lipid formulations is listed in table 1.1  
 
Table 1.1: The typical composition of various types of lipid formulations (Pouton, 
2006) 
 
Excipients in formulation 
Content of lipid based formulation (%, 
w/w) 
Type 
I 
Type 
II 
Type 
IIIA 
Type 
IIIB 
Type 
IV 
Oils: triglycerides or mixed mono 
and diglycerides  
100 40 - 80 40 - 80 <20 - 
Water-insoluble surfactants 
(HLB < 12) 
- 20 - 60 - - 0 -20 
Water-soluble surfactants 
(HLB > 12) 
- - 20 - 40 20 - 50 30 -80 
Hydrophilic co-solvents  - - 0 - 40 20 -50 0 - 50 
 
1.4 Self-emulsifying drug delivery system (SEDDs) 
Out of the four discussed types of lipid-based formulations, self-emulsifying drug 
delivery system (SEDDs) are the most used colloidal dispersions in the experimental 
and commercial fields (Kalepu et al., 2013; Hauss, 2007). Prior to formulation, the 
proper selection of SEDDs constituents is highly essential in order to know each 
component’s properties, and employ them to match the selected drug nature and the 
intended research aim. Drug solubility in the nominated excipients is the first 
parameter to consider, along with pseudo ternary diagram construction. 
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1.4.1 Advantages and disadvantages of SEDDs 
SEDDs were found to have many advantages, including increasing drug solubility, 
enhancing its dissolution rate (Gurram et al., 2015), and increasing membrane fluidity 
to facilitate transcellular absorption either through reducing the trans-epithelial 
electrical resistance (TEER) through either opening the tight junction (Sha et al., 
2005), or inhibiting cytochrome P450 (CYP450) enzymes (Zhao et al., 2013; Trivedi 
et al., 2013). The anhydrous nature of the formula will add further advantages to it, 
including long-term stability, patient compliance, ease of manufacturing and scale up. 
The limitation of SEDDs is summarized in their high content of surfactants and co-
surfactants (Smix), which increased the safety concerns. Thus, conducting cytotoxicity 
studies for almost every designed formula is recommended. The high surfactant/co-
surfactant mixture (Smix) ratio might lead to drug’s degradation and instability 
(Shobhit et al., 2012).  
 
1.4.2 Dilution impact on SEDDs behaviour 
Upon dilutions, SEDDs spontaneously form a nano or micro emulsion based on the 
formulation design, HLB values, materials and drug’s physiochemical nature. The 
formed nano-emulsions are having a stable particle size upon different dilution ratios, 
ranging from10 to 300 nm, and considered kinetically stable. Its formation is highly 
dependent on the components mixing order (a surfactant first mixed with an oil) at 
room temperature. On the other hand, micro-emulsions are highly dependent on the 
thermodynamic variables such as temperature and composition. A wide range of 
particle structures can be detected within a one micro-emulsion involving the 
formation of many phases at equilibrium (up to three) in the same flack, that have 
different types of nano-metric scaled morphologies (Kahlweit et al., 1990) including 
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worm-like, bi-continuous sponge-like, liquid crystalline, or hexagonal, spherical 
swollen micelles, Anton & Vandamme, (2011).  
 
1.4.3 SEDDs constituents and their role 
The SEDDs constituents’ selection are based on general parameters such as purity, 
stability, cytotoxicity and irritancy, solvents capacity and miscibility. Other properties 
such as self-dispersion, digestibility and the safe elimination of the digested products 
are also needed to be considered during material selection. Moreover, using low cost 
materials will always be an additional point, Pouton & Porter, (2008).  
 
1.4.3(a) Oil  
Naturally, oil phase plays a critical role in solubilizing a lipophilic drug or isolated 
substance, and facilitating self-emulsification. Besides that, oil also boosts the GIT 
absorption of the drug by increasing its transport via the intestinal lymphatic system 
(Gershanik & Benita, 2000; Lindmark et al., 1995; Charman & Stella, 1991), thus, 
altering the drug biopharmaceutical properties. Researchers have used long, medium 
and short chain fatty acids with different degrees of saturation (Caliph et al., 2000). 
The edible type of vegetable oils showed a low capacity to dissolve drugs, while the 
modified or hydrogenated vegetable oil were more commonly used, as they have 
higher capability to dissolve drugs, and formed good emulsification systems (Gupta et 
al., 2013; Constantinides, 1995). Moreover, semi-synthetic medium chain derivatives 
with amphiphilic nature and surfactant properties, are progressively replacing the 
regular medium chain triglyceride oils in the SEDDs, Neslihan & Benita, (2004).  
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1.4.3(b) Surfactants  
Various types of surfactants with different HLB values ranging from 2 to 18 have been 
used for SEDDs development, Rajan & Nirav, (2011). Their usage boosts drug 
dissolution rate and cellular permeation Neslihan & Benita (2004). Safety is the major 
concern to be considered in surfactants selection. Natural emulsifiers are safer than 
synthetic ones, but they have limited emulsification capacity (Constantinides, 1995). 
Non-ionic surfactants (with high HLB values) are dominating other surfactants types 
within SEDDs formulation because they are less toxic compared to ionic surfactants 
(Seema et al., 2016; Swenson et al., 1994). Usually, stable SEDDs are containing a 
surfactant concentration between 30 to 60%. Increasing surfactant concentration will 
create a dispersion with a smaller particle size, but after a certain limit, particle size 
will start to increase (Kommuru et al., 2001).  
 
1.4.3(c) Co-surfactants and co-solvents 
The addition of a co-surfactant to the SEDDs formulation may help to reduce the 
amount of surfactant used especially if a high surfactant concentration is needed. The 
synergistic surfactant/co-surfactant effect would lower the interfacial tension to form 
fine droplets (Swain et al., 2016).  
 
Co-solvents are used to induce SEEDs homogeneity, stability, and to increase the 
solubility of the incorporated drug in the designed formula, they usually enhance the 
hydrophilic surfactants dispersion in the oil phase. Medium length chain alcohols (C8 
– C12) are usually selected for SEEDs studies, along with ethylene-glycol, glycerol, 
and propylene glycol derivatives (Swain et al., 2016).  
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1.4.4 Mechanism of self -emulsification 
The full description of the self-emulsification process is still not clear. A self-
emulsified dosage forms is a mixture of an oil and surfactant, whereby the addition of 
water it will form an emulsion with little or no energy input. Such emulsion will deliver 
the drug to the GIT in an emulsified form that creates a high surface area for 
dissolution, hence improves drug bioavailability (Craig et al., 1995).  
 
During the formation of a classical emulsion, the excess surface free energy is 
dependent on the droplet size and the interfacial tension. Surfactants are employed to 
stabilize the emulsion and prevent the phase separation via reducing the interfacial 
tension and the free energy (Craig et al., 1995). However, in SEEDs formation, the 
free energy is very low, hence resulted in thermodynamic spontaneous emulsification. 
Scientists suggested that self-emulsification occurs due to water penetration into the 
liquid crystalline (LC) phase that is formed at the oil/surfactant-water interface and 
during gentle agitation. This LC phase is probably the reason behind the high stability 
of the resulting nano-emulsion against coalescence (Groves & de Galindez, 1976; 
Wakerly et al., 1986).    
 
1.4.5 Conversion of liquid SEDDs to solid SEDDs  
Liquid SEDDs (L-SEDDs) could be converted into solid state SEDDs (S-SEDDs) 
which can be formulated in different pharmaceutical dosage forms such as tablets, 
pellet or capsules. This conversion is made to combine the advantages of both L-
SEDDs and S-SEDDs in one dosage form. S-SEDDs are known for their low 
production cost, convenience of process control, high stability, reproducibility and 
patient compliance. Researchers have adopted various techniques to obtain S-SEDDs 
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including spry drying, adsorption to solid carriers (Tang et al., 2008), extrusion 
spheronization (Fanun, 2016), and melt granulation (Chambin et al., 2004). 
 
1.4.6 Food impact on the absorption of drugs loaded SEDDs  
 SEDDs lipidic constituents are similar to dietary lipids existing in daily food. Usually, 
larger quantities of lipid (> 2 g) are capable of stimulating additional bile secretion; 
hence increase the luminal concentration of bile. This will provide a lipidic 
microenvironment for forming emulsion droplets, that will be transformed into various 
components such as vesicular and micellar phases (Kollipara & Gandhi, 2014). 
Researchers reported that the administration of poorly soluble drugs in SEDDs 
formulations would make the drug less sensitive toward food intake compared to the 
drugs in their pure forms (Woo et al., 2008; Nielsen et al., 2008). Cinnarizine SEDDs 
capsules and SEDDs tablets were capable of reducing the food effect on the drug 
absorption in dogs (Christiansen et al., 2014). The concomitant administration of blank 
SEDDs with cinnarizine tablets to 10 healthy volunteers was able to reduce the food 
effect on the absorption of the drug (Christiansen et al., 2016).  
 
1.5 Azithromycin 
Azithromycin (AZM) is a semi-synthetic 15-membered macrolide antibiotic and the 
first azalide in the market with a superior antibacterial activity among its family 
members for the last three decades. The drug was approved by USFDA in 1991. AZM 
was synthesized in an attempt to produce an acidic stable macrolide, with a wider 
bacterial spectrum, and longer half-life (Imperi et al., 2014).  
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1.5.1 Physiochemical properties 
AZM (chemical structure in figure 1.2) is an amorphous powder, slightly water soluble 
(2.37 mg/L at 25 ◦C), with a melting point of 114°C, and LogP of 4.02 as well as a pKa 
of 8.74 (at 25 ◦C) (U.S. National Center for Biotechnology Information, 2016). The 
anhydrous AZM is having a relatively large molecular weight of 749.0 Da (Luke & 
Foulds, 1997). 
 
 
Figure 1.2: Structure of azithromycin 
 
1.5.2 Biopharmaceutical classification (BCS) of AZM 
The World Health Organization (2005) described AZM biopharmaceutical 
classification as either Class III (high aqueous solubility with low permeability), or 
Class IV (poor aqueous solubility with poor permeability). Moreover, Gandhi et al. 
suggested that AZM should be in class III of the biopharmaceutical classification. The 
authors made their conclusion based on the results obtained by reviewing the published 
literatures about AZM in the Medline (Gandhi et al., 2014). 
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1.5.3 Pharmacological actions 
AZM is active against a wide range of gram-positive and gram-negative organisms 
(Peters et al., 1992; Williams, 1991). It is the drug of choice for the treatment of 
community-acquired pneumonia (Kuzman et al., 1995), typhoid fever (Butler et al., 
1999), Shigella dysenteriae (Niyogi, 2005), trachoma (Chen et al., 2010), non-
gonococcal urethritis (Carlin & Barton, 1996), and skin infections (Mallory, 1991). 
AZM inhibits the protein synthesis in bacteria by binding to the 50s ribosomal subunit 
and preventing the translocation of peptides (Bekaert & White, 2006), which 
accordingly inhibits the RNA dependent protein synthesis (Learning, 2012). 
 
The oral intake of AZM is associated with `GIT adverse effects, including 
diarrhoea/loose stools, nausea, and abdominal pain. About 1-2% of the patients under 
AZM medication experienced elevations in ALT (SGPT), AST (SGOT), or gamma-
glutamyltransferase (GGT, GGTP). Intravenous infusion of AZM may cause adverse 
effects include pain at the injection site or local inflammation occurred in 6.5 % or  3.1 
% of patients respectively (U.S. National Center for Biotechnology Information, 
2016). 
 
1.5.4 Pharmacokinetics  
AZM has a wide therapeutic index and low bioavailability of 37 %.  The oral dosing 
regimen is 500 mg daily for three days, or alternatively 500 mg as initial dose followed 
by 250 mg daily for a period of four days (Naieni & Akrami, 2006). AZM is 
metabolized hepatically by demethylation, (Schlagenhauf-Lawlor, 2007). AZM 
elimination is via bile excretion (Kee et al., 2014), it is largely found unchanged in 
urine and stool (Yaffe & Aranda, 2010). AZM tissue concentrations exceed serum 
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concentrations by 10- to 100 folds, with a slow release pattern of AZM from tissues, 
leading to a very long half-life (68 h), and an elimination half-life of 3 days. Such 
profiles permit once a day dosing with a short treatment period in many cases (Katzung 
et al., 2012; Pfizer Laboratories, 2016).  
 
The drug absorption capacity within the small intestine is linked with the accessibility 
of it to the GI mucosal surface, where absorption occurs Arcangelo & Peterson (2006). 
Food intake was found to have different impacts on AZM based on its consumed 
pharmaceutical dosage form. Administration of AZM capsules with food reduced its 
rate of maximum concentration (Cmax) by 52 %, and the extent of the area under the 
curve (AUC) by 43 %. In contrast, food intake with AZM oral suspension, increased 
the Cmax and the AUC by 46 % and 14 % respectively. While the intake of AZM tablets 
with food increased the drug tolerability, and the Cmax by 31%, but the AUC remained 
unchanged (Pfizer Laboratories, 2016; USFDA, 2012). 
 
1.6 Literature review 
1.6.1 Nanotechnology based techniques in enhancing AZM oral solubility and 
bioavailability  
Various nanocarriers were investigated to enhance AZM oral delivery and improve its 
anti-bacterial properties. AZM conjugated with neutral polyamidoamine dendrimers 
were more influential than the conventional AZM against Chlamydia trachomatis at 
its persistent infectious form (Mishra et al., 2011). AZM microcapsules with an 
average diameter of 1.2 µm had higher dissolution rate compared to the pure AZM 
(Zhang et al., 2010). While AZM microspheres with a larger particle size (11.65 – 
14.45 µm) were also able to improve the drug dissolution profile (Li et al., 2012). 
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Other studies observed that AZM nano suspension prepared using different polymers 
had higher dissolution rate and a sustained release property (Kaushik et al., 2015) with 
a particle size of 200 nm and improved drug solubility (Hou et al., 2012). Zhang et al 
found that AZM-nanosuspension size of 400 nm showed a better release performance 
than the micro scale one (Zhang et al., 2007). 
 
Nanoparticles of AZM with a particle size  of 212 to 252 nm prepared using different 
ratios of poly(lactide-co-glycolide) (PLGA) polymer were found to improve AZM 
potency against a wide range of bacteria by modifying AZM surface characteristics, 
its adsorption to the bacterial cells and uptake (Mohammadi et al., 2010; Azhdarzadeh 
et al., 2012). Noble metals nanoparticles of AZM silver (15 to 30 nm), and gold (20 to 
40 nm) were proven safe, and were able to increase AZM antibacterial activity against 
E.coli and Staphylococcus aureus (Namasivayam & Samrat, 2016; Namasivayam & 
Ganesh, 2012).  
 
Darabi et al. reported that some AZM nanotubes were able to enhance its penetration 
in a Micrococcus luteus cell culture model, and increase the antimicrobial activity 
(Darabi et al., 2014). The bioavailability of AZM was also enhanced by using a 
cationic niosomes-based delivery systems (0.95 – 5.87 µm) (Zhong et al., 2014). 
Recently, AZM-nanofibers (100-300 nm) and nanobeads (100-500 nm) were 
developed using Eudragit® RS100 polymer, and were able to boost AZM minimum 
inhibitory concentrations, and increased its antimicrobial activity against S. pneumonia 
(Adibkia et al., 2016).  
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1.6.2 L-SEDDs and S-SEDDs in drug delivery 
L-SEDDs (liquid SEDDs) and S-SEDDs (solid SEDDs) are utilized and studied to 
produce advanced dosage forms of conventional drugs; and they ended up as marketed 
products under the licence of leading companies within the pharmaceutical industry. 
L-SEDDs and S-SEDDs have enhanced drug’s performance through improving their 
solubility, bioavailability and permeability. These nanocarriers have reduced the 
administered doses of different drugs by improving their Cmax, which in turn reduced 
the side effects of loaded drugs in comparison to their conventional forms. The rapid 
onset of action of L-SEDDs and S-SEDDs offer faster drug therapy. This is particularly 
important in cases where the fast pharmacological action is needed such as in 
inflammation, hypertension and angina conditions (Nepal et al., 2010). S-SEDDs 
formulations are preferred from pharmaceutical point view over L-SEDDs 
formulations as they provide more flexibility to formulate a wider range of dosage 
forms. Nevertheless, until now there is no clear conclusion whether L-SEDDs or S-
SEDDs is superior for oral drug delivery based on the conflicting results that were 
reported in the literatures. In an in vivo study, L-SEDDs showed superiority results in 
the delivery of cyclosporine A in comparison to its S-SEDDs form (Kim et al., 2001). 
Another study showed that both the S-SEDDs and L-SEDDs of progesterone had 
similar in vitro and in vivo profiles (Tuleu et al., 2004). The in vitro assay revealed that 
the efficacy of L-SEDDs and S-SEDDs was similar for cilnidipine (Bakhle & Avari, 
2015), and fenoﬁbrate (Shazly & Mohsin, 2015). Fexofenadine loaded L-SEDDs and 
S-SEDDs had similar potentials in increasing the oral bioavailability through 
enhancing the dissolution rate, blocking the P-glycoprotein efﬂux pump, and CYP450 
hepatic metabolism (Trivedi et al., 2013). The L-SEDDs were superior to S-SEDDs in 
term of physiochemical properties when loaded with atorvastatin. However, in this 
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case S-SEDDs showed a much better dissolution rate indicating better solubilisation 
properties (Kosnik et al., 2015).  
 
In general, L-SEDDs and S-SEDDs are considered as stable lipidic formulations 
(Wang et al., 2008). S-SEDDs were stable for the period of three months at room 
temperature as well as at 40 °C (Jaiswal et al., 2014). L-SEDDs and S-SEDDs loaded 
with tacrolimus were evaluated for enhancing bioavailability and their shelf life in two 
different studies at 25 °C. Shelf life in the first study was 1.84 and 2.25 years (Patel et 
al., 2013); while in other study it was 1.76 and 2.27 years, respectively (Hitesh et al., 
2012). Moreover, both types of formulations had similar efficacy in enhancing drug’s 
bioavailability. Thus, it can be concluded that the properties of L-SEDDs or S-SEDDs 
are very much influenced by the constituent’s nature, HLB value, properties of drug 
to be incorporated and preparation method.  
 
1.6.3 Marketed SEDDs formulations 
The first marketed drug in the form of SEDDs was cyclosporine A (Sandimmune®), 
and later other products were also introduced into the market, including ritonavir 
(Norvir®), as well as Saquinavir (Fortovase®). These formulations had shown to 
improve the bioavailability of drugs significantly compared to the conventional 
formulations (Hu & Li, 2011). Examples of the marketed pharmaceutical products 
formulated as self- emulsifying systems (SEDDs) are shown in table 1.2. 
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Table 1.2: Examples of pharmaceutical products formulated as self-emulsifying drug 
delivery systems Rajan & Nirav (2011)  
 
Drug name Compound Dosage form Company 
Neoral Cyclosprorine Soft gelatin capsule Novartis 
Norvir Ritonavir Soft gelatin capsule Abbott laboratories 
Fortovase Saquinavir Soft gelatin capsule 
Hoffmann-
La Roche lnc. 
Agenerase Amprenavir Soft gelatin capsule Glaxosmithkline 
Solufen Ibuprofen Hard gelatin capsule Sanofi- Aventis 
Lipirex Fenofibrate Hard gelatin capsule Sanofi- Aventis 
 
 
1.7 Problem statement  
The effort to improve the solubility and dissolution of a poorly water-soluble drug 
remains one of the most challenging tasks in drug development. Azithromycin low 
solubility in water and biological fluids is considered as the major contributing factor 
to its erratic and low dissolution rate as well as its low bioavailability (37 %) after oral 
administration; this is mostly linked to its hydrophobic nature and high molecular 
weight. Such low oral bioavailability leads to a high oral dose of azithromycin, longer 
terms of medication and greater related gastrointestinal side effects. On the cellular 
level, azithromycin was reported to have a tendency to increase the tight junctions 
closing through increasing the transepithelial electrical resistance values, hence 
affected the azithromycin paracellular transport, and reduced its intestinal 
permeability. 
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Furthermore, I.V injection, the only alternative route of drug administration, has been 
associated many side effects, including erythema, pain, swelling and tenderness at the 
site of injection. SEDDs formulations had shown promising results in improving wide 
range of lipophilic drug delivery through enhancing their solubility, dissolution rate, 
bioavailability, and altering their cellular penetration mechanisms. Thus, SEDDs could 
have a potential in improving the oral delivery of azithromycin. 
 
1.8 Objectives 
The objectives of this study are to: 
I. Develop and validate a stability indicating HPLC method for azithromycin 
(AZM) in bulk and AZM loaded self-emulsifying drug delivery system 
(AZM-SEDDs).  
II. Design and characterize the AZM-SEDDs in the form of liquid and solid 
formulations. 
III. Investigate the ability of liquid and solid AZM-SEDDs to enhance AZM 
solubility, and dissolution rate in different PH values. 
IV. Evaluate the developed liquid and solid AZM-SEDDs formulations safety 
on a Caco-2 model. 
V. Investigate the ability of the AZM-SEDDs to reduce the transepithelial 
electrical resistance tight junctions on a Caco-2 model. 
VI. Evaluate the stability and shelf life of  the liquid and solid formulations of 
AZM-SEDDs  
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CHAPTER 2 
DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING 
HPLC METHOD FOR THE QUANTIFICATION OF AZITHROMYCIN IN 
SELF-EMULSIFYING DRUG DELEIVERY SYSTEM 
 
2.1 Introduction 
The ultraviolet-visible (UV-Vis) spectrophotometry is the most widely used 
quantitative method in the pharmaceutical analysis due to its simplicity and rapidness 
(Siladitya et al., 2012). However, azithromycin (AZM) ultraviolet (UV) detection is 
highly challenging due to the absence of the conjugated double bond in its lactone ring, 
which consequently results in a low molar absorptivity (Kanfer et al., 1998). Thus, it 
is necessary to develop an HPLC method for the quantification of AZM in pure and 
self-emulsifying drug delivery system (AZM-SEDDs) forms for the in vitro release, 
and further studies. 
 
Different techniques have been used to quantify AZM in various biological fluids and 
pharmaceutical dosage forms including LC–MS/MS (Shen et al., 2010), thin layer 
chromatography-densitometry method (Kwiecień & Gadek 2013; Khedr & Sheha, 
2003), cyclic voltammetry and square-wave voltammetry methods using different 
electrodes  (Peng et al., 2011; Avramov et al., 2006; Farghaly & Mohamed, 2004; 
Nigović & Šimunić 2003) and Raman spectroscopy quantification by measuring 
drug’s peak intensity (Shende et al., 2014). However, these methods are either 
expensive, tedious or time consuming in comparison to a simple HPLC-UV method. 
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Based on literature review, some HPLC-UV methods have been developed to detect 
AZM in pharmaceutical dosage forms (Shaikh et al., 2008; Kulikov & Verushkin, 
2004). However, only few methods were reported under stability indicating conditions 
(Subbareddy, 2015; Ramesh M., 2012; El-Gindy et al., 2011; Al-Rimawi & Kharoaf, 
2010). Moreover, despite the fact that HPLC-UV techniques were used to quantify 
AZM in some nano-formulations, but the validation of these methods was not 
mentioned (Zhong et al., 2014; Pouretedal, 2014; Yan et al., 2009). 
 
Accordingly, the aim of this work is to develop a simple, specific and reproducible 
stability indicating HPLC–UV method for the determination of AZM in bulk, AZM-
SEDD and in different in vitro release mediums. The method was developed and 
validated as per the recommendations of the International Conference on 
Harmonization ICH guideline (ICH, 2005). 
 
2.2 Materials and methods 
2.2.1 Materials 
Azithromycin anhydrous (purity > 97.2%) was a kind gift from Wockhardt Research 
Centre (Aurangabad, India). Acetonitrile and methanol (HPLC grade) were purchased 
from J.T. Baker (Phillipsburg, USA). Ammonium acetate was bought from Bendosen 
Laboratory Chemicals (Bendosen, Norway). Tween 20® (Polyethylene glycol sorbitan 
monolaurate) was purchased from Sigma-Aldrich (St. Louis, Missouri, USA), Capryol 
90® (Propylene glycol monocaprylate) and Transcutol HP® (Diethylene glycol 
monoethyl ether) were purchased from Gattefossé (Lyon, France). All other chemicals 
used were of analytical reagent grade and obtained commercially. 
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2.2.2 Instrumentation 
The study was conducted on a Shimadzu liquid chromatography system (VP series, 
Kyoto, Japan) with CBM/20A system controller, LC/20AD solvent delivery pump, 
SPD/20A UV/VIS detector, SIL/20A auto-sampler, and CTO/10ASvp oven system. 
Data acquisition and analysis were performed using Shimadzu LabSolutions® software 
(version 5.30 SP1) (Kyoto, Japan). 
 
2.2.3 Chromatographic condition 
The chromatographic separation was performed using a Hypersil GOLD C-18 
analytical column with the dimensions of 250 mm x 4.6 mm ID x 5 µm, Fisher 
Scientific (Waltham, Massachusetts, USA). The ﬂow rate was set at 0.7 ml/min, and 
the detection wavelength was set to 210 nm. The oven temperature was maintained at 
60 ºC, and an injection volume of 10 µl was employed. Mobile phase was consisting 
of acetonitrile: ammonium acetate solution (30 mM, pH = 6.8) (82:18 v/v). The mobile 
phase was ﬁltered through nylon membrane ﬁlter 0.45 µm Titan®, Thermos Scientific 
(Waltham, Massachusetts, USA), sonicated and degassed before used. All samples 
were filtered before injection using syringe filter 0.2 µm Pall (New York, USA). 
 
2.2.4 Preparation of stock solution, calibration standards and quality control 
samples 
The standard stock solution of AZM (5000 µg/ml) was prepared by dissolving 50 mg 
of AZM powder in 10 ml of the methanol and sonicated in ultrasonic bath (Branson 
5510, USA) for 2 min. Then it was further diluted with the diluting solution (which 
consist of acetonitrile: ammonium acetate solution (60:40 v/v) to obtain a working 
standard solution of 1600 µg/ml. Solutions for the calibration were prepared by 
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diluting the working standard solution with the diluting solution to give concentrations 
in the range of 5 to 200 µg/ml. Three quality control (QC) solutions at low (LQC), 
medium (MQC) and high (HQC) concentrations were prepared of 15, 100 and 180 
µg/ml, respectively.  
 
2.2.5 System suitability studies 
System suitability tests were conducted to verify the performance and the 
reproducibility of the chromatographic system. Analytical parameters such as 
retention time (Rt), theoretical plates (N), tailing factor (T), and resolution (Rs) were 
checked at the three QC concentrations in six injection replicates.  
 
2.2.6 Specificity 
The specificity test is a reflection of the analytical method capacity in measuring the 
drug in the presence of impurities, excipients, and degradation products (if any). The 
test was done by comparing the chromatograms of the mobile phase, AZM standard 
solution, blank-SEDD, AZM-SEDDs, in vitro release mediums, 0.1 mM HCl solution 
(pH = 4), and simulated intestinal fluid (SIF, pH = 6.8). 
 
2.2.7 Stress degradation studies 
The stress degradation studies were done to measure the ability of the developed 
method to assess unequivocally the analyte in the presence of components such as 
degradation products, impurities, and excipients (ICH, 2005). In this study, the stress 
degradation conditions of acid, base, oxidation, heat and light were performed on four 
solutions namely: AZM standard, AZM-SEDD, blank-SEDD and mobile phase. The 
AZM standard solution of 1600 µg/ml was prepared by diluting the required volume 
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of the standard stock solution with methanol. A volume of 0.27 ml of AZM-SEDD (60 
mg/ml AZM) was dissolved in methanol to get the AZM concentration of 1600 µg/ml. 
The blank-SEDD solution was prepared similar to AZM-SEDD solution. The mobile 
phase was used as it is. 
 
2.2.7(a) Acid and alkali degradation studies 
For acid degradation study, two sets of four 10 ml flasks were filled in with 1 ml of 
AZM standard, AZM-SEDD, blank-SEDD or mobile phase, respectively. 
Subsequently, 1 ml of 1 mM HCl was added to all the flasks. The solutions in the first 
set were neutralized immediately with 1 ml of 1 mM NaOH, then the diluting solution 
was added up to 10 ml. These solutions were served as zero hour samples. The 
solutions in the second set were left on the bench at room temperature (25 ± 2 ºC/65 ± 
5 % relative humidity) for 24 h, then neutralized and diluted by the same way. These 
solutions were served as 24 h samples. All the samples were injected in triplicate. 
For alkali degradation study, similar procedure was used, but 1 ml of 100 mM NaOH 
was added to each flask instead of 1 ml of 1 mM HCl and the neutralization procedures 
were done using 100 mM HCl.  
 
2.2.7(b) Oxidative hydrogen peroxide (H2O2) degradation 
Two sets of four 10 ml flasks were filled in with 1 ml of AZM standard, AZM-SEDD, 
blank-SEDD or mobile phase, respectively. Subsequently, 1 ml of 3 % H2O2 was added 
to all the flasks. The solutions in the first set were immediately diluted with diluting 
solution up to 10 ml. These solutions were served as zero hour samples. The solutions 
in the second set were left on the bench at room temperature (25 ± 2 ºC/65 ± 5 % 
